Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis

Next Previous
Trial Profile

A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 17 Oct 2023 Results assessing final safety analyses from the tofacitinib UC ((NCT00787202; NCT01465763; NCT01458951; NCT01458574,NCT01470612, NCT03281304) presented at the 31st United European Gastroenterology Week
    • 02 May 2023 Results assessing CDI in the tofacitinib UC clinical program from (NCT00787202; NCT01465763; NCT01458951,NCT01458574,NCT01470612) published in the Inflammatory Bowel Diseases
    • 05 Jan 2023 Results assessing age as a risk factor for adverse events of special interest (AESI) in the tofacitinib ulcerative colitis studies NCT00787202; NCT01465763; NCT01458951; NCT01458574; NCT01470612, published in the Inflammatory Bowel Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top